Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

• Status: Completed
• Trial end date: 2021-01-13

Summary

The goal of this clinical research study to find the highest tolerated dose of anastrozole alone or in combination with either everolimus (Afinitor), sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or bevacizumab (Avastin) that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied.

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Anastrozole; Antibodies; Antibodies, Monoclonal; Bevacizumab; Erlotinib Hydrochloride; Everolimus; Hormones; Sirolimus; Sorafenib